Core Insights - LifeVantage Corporation will release its financial results for the fourth quarter and full fiscal year ended June 30, 2025, on September 4, 2025, after market close [1] - A conference call for investors will take place on the same day at 2:30 p.m. Mountain Time [1] Financial Results Announcement - The financial results will cover the fourth quarter and the full fiscal year ending June 30, 2025 [1] - The announcement will be made after the stock market closes on September 4, 2025 [1] Conference Call Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and will last until September 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]

Core Insights - LifeVantage Corporation is set to launch its products in Iceland in September 2025, marking a significant step in its international expansion strategy [1][4] - The launch will feature a selection of top-performing products and three curated wellness stacks tailored to various health goals, with plans for additional products in the future [2][4] - The introduction of the LifeVantage business opportunity in Iceland will be supported by the Evolve Compensation Plan, allowing consultants to enroll for the launch [3][4] Company Overview - LifeVantage Corporation specializes in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [6] - The company's product line includes scientifically validated activators such as Protandim®, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [6][7] - LifeVantage operates through independent consultants who sell products and promote business opportunities to aspiring entrepreneurs [6] Leadership Perspective - Steve Fife, President and CEO, expressed excitement about the Iceland launch, emphasizing its role in empowering individuals with health tools and supporting their entrepreneurial journeys [4]

Financial Data and Key Metrics Changes - The company's net sales for Q1 2025 were $1.2 billion, down 3.4% compared to Q1 2024, which was just above the midpoint of the guidance range [9][28] - On a constant currency basis, net sales grew by 1.4% year over year, marking the second consecutive quarter of growth excluding foreign exchange headwinds [10][28] - Adjusted EBITDA for Q1 was $165 million, exceeding guidance, with adjusted EBITDA margins at 13.5%, up 260 basis points year over year [29][38] - The total leverage ratio was reduced to three times as of March 31, achieving the target set for the end of 2025 nine months ahead of schedule [10][33] Business Line Data and Key Metrics Changes - The number of new distributors joining Herbalife worldwide increased by 16% year over year, marking the fourth consecutive quarter of new distributor growth [11] - The company reported a gross profit margin improvement to 78.3%, up 80 basis points compared to Q1 2024, primarily due to pricing actions and reduced input costs [29] Market Data and Key Metrics Changes - In Latin America, net sales were down 4% on a reported basis but up 11% on a local currency basis, driven by favorable pricing and a 4% increase in volumes [35] - North America saw a 4% decline in net sales year over year, primarily due to an 8% reduction in volumes [37] - China experienced a 14% decline in net sales year over year on a reported basis, driven by a 14% decrease in volumes [37] Company Strategy and Development Direction - The company aims to lead in the health and wellness economy by leveraging its network of 2.1 million distributors and enhancing its product offerings through technology and personalization [7][8] - Recent acquisitions of Protocol Health, Pruvit Ventures, and Link Biosciences are intended to strengthen the company's position in the market and enhance its product portfolio [12][21] - The focus will be on innovation, operational excellence, and sustainable growth, with an emphasis on AI-powered solutions and personalized health programs [9][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to adapt to changing consumer expectations and the gig economy, viewing these changes as opportunities for growth [6][9] - The company expects FX to remain a significant headwind for the remainder of 2025, impacting both net sales and adjusted EBITDA [43][45] - The outlook for Q2 2025 includes expectations for net sales to be in the range of down 3.5% to up 0.5% year over year, with a constant currency basis expecting a range of down 0.5% to up 3.5% [44] Other Important Information - The company plans to launch a beta version of the Protocol platform in July 2025, with a commercial release planned for Q4 2025 [17][18] - The total cash consideration paid for recent acquisitions was $25.5 million, with contingent payments of up to $5 million based on successful launches [42] Q&A Session Summary Question: Can you expand on the monetization strategy of Protocol and its impact on conversion rates at U.S. Nutrition clubs? - Management acknowledged that it is early to discuss ROI but emphasized the potential for the digital platform to enhance product consumption and distributor engagement [49][50] Question: What is driving the sequential decline in distributor numbers and volumes in North America? - Management noted that the U.S. market started strong but faced challenges in February, with expectations for improvement in Q2 [60][62] Question: Why was the midpoint of the constant currency sales guidance for 2025 reduced? - Management explained that the reduction reflects the Q1 trend and some weakness in Asia Pacific, particularly in China, while still expecting overall growth [64][66] Question: What are the intentions for Link Biosciences and its target audience? - Management indicated that Link Biosciences will cater to both athletes and a broader audience seeking customized health solutions, positioning the company ahead of competitors [70][74] Question: How does the current economic environment impact the business? - Management suggested that direct sellers historically perform well in cyclical environments where consumers seek additional income [87]

Financial Data and Key Metrics Changes - The company's net sales for Q1 2025 were $1.2 billion, down 3.4% compared to Q1 2024, but showed a constant currency growth of 1.4% year over year [10][27] - Adjusted EBITDA for Q1 was $165 million, exceeding guidance, with adjusted EBITDA margins at 13.5%, up 260 basis points year over year [28] - The total leverage ratio was reduced to three times as of March 31, achieving the target set for the end of 2025 nine months ahead of schedule [11][31] Business Line Data and Key Metrics Changes - The number of new distributors joining Herbalife worldwide increased by 16% year over year, marking the fourth consecutive quarter of new distributor growth [12] - The company reported a gross profit margin improvement to 78.3%, up 80 basis points compared to Q1 2024, driven by pricing actions and reduced input costs [28] Market Data and Key Metrics Changes - In Latin America, net sales were down 4% on a reported basis but up 11% on a local currency basis, with a 4% increase in volumes [33] - EMEA net sales were down 2% year over year on a reported basis, while up 3% on a local currency basis, with a 5% decline in volume [34] - North America saw a 4% decrease in net sales year over year, primarily due to an 8% reduction in volumes [35] Company Strategy and Development Direction - The company aims to lead in the health and wellness economy by leveraging its distributor network and enhancing its product offerings through technology and personalization [7][8] - Recent acquisitions of Protocol Health, Pruvit Ventures, and Link Biosciences are intended to strengthen the company's position in personalized health solutions [13][21] - The focus will be on innovation, operational excellence, and sustainable growth rather than just short-term gains [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to adapt to changing consumer expectations and the gig economy, viewing these changes as opportunities for growth [6][8] - The company expects FX to remain a significant headwind for the remainder of 2025, impacting both net sales and adjusted EBITDA [40][43] - The outlook for Q2 2025 includes expected net sales to range from down 3.5% to up 0.5% year over year, with a constant currency basis expectation of down 0.5% to up 3.5% [41][44] Other Important Information - The company plans to launch a beta version of the Protocol platform in July 2025, with a commercial release planned for Q4 2025 [17][18] - The total cash consideration paid for recent acquisitions was $25.5 million, with contingent payments of up to $5 million based on successful launches [39] Q&A Session Summary Question: Can you expand on the monetization strategy of Protocol? - Management indicated that it is early to discuss ROI, but the digital platform aims to support product consumption and distributor engagement [47][50] Question: What is driving the sequential decline in distributor KPIs in North America? - Management noted that the quarter started strong but faced challenges in February, with expectations for improvement in Q2 [61][63] Question: Why was the constant currency sales guidance for 2025 reduced? - The reduction was primarily due to rolling in Q1 trends, with some weakness noted in Asia Pacific and cautious expectations for China [66][67] Question: What are the intentions for Link Biosciences? - The company aims to target both athletes and a more general audience, focusing on hyper-customization in health products [71][75] Question: Is there any additional CapEx associated with the recently acquired assets? - Management confirmed that the CapEx guidance was lowered due to underspending in Q1, but future months will include necessary expenditures for the acquisitions [92][93]

Core Insights - LifeVantage Corporation successfully concluded its annual Global Convention in Salt Lake City, attended by over 2,000 Independent Consultants from around the world, focusing on business updates, product announcements, and training initiatives [1][2] Group 1: Product Launch and Expansion - The MindBody GLP-1 System™, previously available in the U.S. and Japan, is now launched for consumers in Europe, Mexico, Thailand, Australia, and New Zealand, marking a significant step in LifeVantage's global expansion [2] - Clinical study results revealed that both the MindBody GLP-1 System™ and MB System™ increased GLP-1 levels in the body by over 200 percent on average [3] Group 2: Sales Incentives and Events - The Drive ERA Q2 Sales Incentive doubles the bonus for Consultants reaching Senior Consultant 1 rank through customer enrollment and retention within the first three months [4] - LifeVantage announced the Executive Destination Trip for North American and European markets will take place in Thailand in 2026, along with the Activate Virtual Event on July 12 and the U.S. Momentum Academy scheduled for October 23-25 in Dallas, Texas [5] Group 3: Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, offering a range of health and wellness products designed to activate optimal health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and AXIO® nootropic energy drink mixes [6]